Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponsegromab in NSCLC Associated Cachexia
NCT07663630Phase 1Not yet recruiting
- Sponsor
- Pfizer
- Start
- Oct 2026
- Primary completion
- May 2028
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in cachexia comparing Placebo + Durvalumab with Ponsegromab + Durvalumab (2 arms). Primary endpoint: Lumbar Skeletal Muscle Index at 12 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ponsegromab
03
Conditions
cachexia
Beyond the preview
Go deeper on NCT07663630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07663630.